Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
Sharon M Moe, Glenn M Chertow, Patrick S Parfrey, Yumi Kubo, Geoffrey A Block, Ricardo Correa-Rotter, Tilman B Drueeke, Charles A Herzog, Gerard M London, Kenneth W Mahaffey, David C Wheeler, Maria Stolina, Bastian Dehmel, William G Goodman, Juergen Floege
CIRCULATION | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
BACKGROUND: Patients with kidney disease have disordered bone and mineral metabolism, including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These elevated concentrations are associated with cardiovascular and all-cause mortality. The objective was to determine the effects of the calcimimetic cinacalcet (versus placebo) on reducing serum FGF23 and whether changes in FGF23 are associated with death and cardiovascular events. METHODS AND RESULTS: This was a secondary analysis of a randomized clinical trial comparing cinacalcet to placebo in addition to conventional therapy (phosphate binders/vitamin D) in patients receiving hemodialysis with secondary hyperparathyroidi..View full abstract
The EVOLVE trial was supported by Amgen Inc.